Key result
Antibody therapies targeting lipids and inflammation offer a personalized approach to reducing MACE in high-risk patients.
Why the study?
Improving cardiovascular risk assessment requires integrating established risk factors with markers such as C-LDL and CRP to guide personalized antibody-based therapies.
Do antibody-based therapies targeting lipids and inflammation improve cardiovascular outcomes in high-risk patients with ischemic heart disease?
Do antibody-based therapies targeting lipids and inflammation improve cardiovascular outcomes in high-risk patients with ischemic heart disease?
The integration of lipid-lowering and anti-inflammatory antibody therapies paves the way for precision medicine in ischemic heart disease.
May support personalized antibody therapies in high-risk IHD; hypothesis-generating and leaves open need for prospective validation.
Improving cardiovascular risk assessment requires a 'personalized' approach. Appraisal of well-known cardiovascular risk factors should be integrated with markers of cardiovascular risk such as LDL cholesterol (C-LDL) and C-reactive protein (CRP). Results of the recent trials of PCSK9 inhibitor monoclonal antibodies open new interesting perspective. Data regarding the use of Evolocumab, in secondary prevention settings, in high-risk patients are very encouraging. In the same vein, the CANTOS study demonstrated, for the first time, that Canakinumbab, an antibody with anti-inflammatory action (with no effects on C-LDL levels), decreases significantly the risk of major cardiovascular events in a high-risk population with elevated CRP and optimal C-LDL. This trial, for the first time, suggested a strategy distinguishing the anti-inflammatory from the cholesterol lowering component, thus differentiating the treatment. In the ensuing years, we will probably witness the clinical application of this concept.
No takes yet. Share an insight, caveat, or question.
Prati et al. (2019) conducted a review in Ischaemic heart disease. Antibody based therapies (Evolocumab, Canakinumab) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: